STOCK TITAN

[SCHEDULE 13G/A] AnaptysBio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Insights

TL;DR: Passive 7.7 % stake by First Light/Arens indicates institutional confidence but no control ambitions; limited direct impact on ANAB fundamentals.

The disclosure shows First Light, a health-care focused adviser, remains above the 5 % threshold with 2.13 m ANAB shares. Passive 13G status signals it is not seeking board seats or driving strategy, reducing the likelihood of near-term governance upheaval. However, a specialist fund maintaining a mid-single-digit position may support liquidity and signal valuation conviction to the market. Absent comparative data to the previous filing, we cannot assess position changes or buying momentum. From a materiality standpoint, ownership concentration around 7 % is noteworthy but unlikely to move the stock without accompanying fundamental catalysts.

TL;DR: Filing is compliant, notes shared voting power; no red flags for control or group formation, impact classified as moderate.

The amendment clarifies beneficial ownership structure, certifying ordinary-course investment and lack of intent to influence control, satisfying §240.13d requirements. Shared power across advisory accounts is standard for asset managers. The absence of a 13D filing or activist language suggests minimal governance risk. Still, management should monitor any future threshold crossings (>10 % or shift to 13D) that could alter control dynamics.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



First Light Asset Management, LLC
Signature:/s/ Kurt T. Peterson
Name/Title:Kurt T. Peterson/Chief Compliance Officer
Date:08/07/2025
Mathew P. Arens
Signature:/s/ Mathew P. Arens
Name/Title:Mathew P. Arens/Chief Executive Officer
Date:08/07/2025
Exhibit Information

Exhibit A: Joint Filing Agreement

Anaptysbio Inc

NASDAQ:ANAB

ANAB Rankings

ANAB Latest News

ANAB Latest SEC Filings

ANAB Stock Data

696.02M
27.86M
5.09%
134.19%
31.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO